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Background: There is growing evidence indicating the insulin-like growth factor 1 receptor (IGF-1R) plays a critical
role in the progression of human colorectal carcinomas. IGF-1R is an attractive drug target for the treatment of
colon cancer. Picropodophyllin (PPP), of the cyclolignan family, has recently been identified as an IGF-1R inhibitor.
The aim of this study is to determine the therapeutic response and mechanism after colorectal carcinoma treatment
with PPP.
Methods: Seven colorectal carcinoma cell lines were treated with PPP. Following treatment, cells were analyzed for
growth by a cell viability assay, sub-G1 apoptosis by flow cytometry, caspase cleavage and activation of AKT and
extracellular signal-regulated kinase (ERK) by western blot analysis. To examine the in vivo therapeutic efficacy of
PPP, mice implanted with human colorectal carcinoma xenografts underwent PPP treatment.
Results: PPP treatment blocked the phosphorylation of IGF-1R, AKT and ERK and inhibited the growth of TP53
wild-type but not mutated colorectal carcinoma cell lines. The treatment of PPP also induced apoptosis in TP53
wild-type cells as evident by the presence of sub-G1 cells and the cleavage of caspase-9, caspase-3, DNA
fragmentation factor-45 (DFF45), poly (ADP-ribose) polymerase (PARP), and X-linked inhibitor of apoptosis protein
(XIAP). The loss of BAD phosphorylation in the PPP-treated TP53 wild type cells further suggested that the treatment
induced apoptosis through the BAD-mediated mitochondrial pathway. In contrast, PPP treatment failed to induce
the phosphorylation of AKT and ERK and caspase cleavage in TP53 mutated colorectal carcinoma cell lines. Finally,
PPP treatment suppressed the growth of xenografts derived from TP53 wild type but not mutated colorectal
carcinoma cells.
Conclusions: We report the association of TP53 mutations with the resistance of treatment of colorectal carcinoma
cells in culture and in a xenograft mouse model with the IGF-1R inhibitor PPP. TP53 mutations often occur in
colorectal carcinomas and could be used as a biomarker to predict the resistance of colorectal carcinomas to the
treatment by this IGF-1R inhibitor.
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The IGF-1R signaling pathway plays an important role
in the formation and progression of human cancers and
has been targeted for cancer treatment [1]. IGF-1R is a
membrane- associated receptor tyrosine kinase that con-
trols both cell growth and apoptosis. Insulin-like growth
factor-I and -II (IGF-I; IGF-II) ligand binding to IGF-1R
leads to the phosphorylation of insulin receptor substrate
(IRS) proteins, resulting in the activation of phosphoinosi-
tide 3-kinase (PI3K)/AKT and downstream signaling path-
ways [2]. IGF-1R inhibits the apoptosis pathway through
AKT-mediated phosphorylation of BAD, a pro-apoptotic
protein of the BCL2 family [3]. Phosphorylated BAD is
dissociated from the BCL-2 family proteins that pro-
tect mitochondrial membrane potential and thus inhibit
mitochondrial release of apoptotic factors [4]. In addition,
IGF-1R activates the extracellular signal-regulated kinase
(ERK) and nuclear factor-κB (NF-κB) pathway that protect
colorectal carcinoma cells from tumor necrosis factor-α
(TNFα) induced apoptosis [5]. By activating PI3K/AKT
and ERK growth pathways and inhibiting the BAD and
TNFα-mediated apoptosis, the IGF-1R signaling path-
way promotes the survival, growth, and metastasis of
colorectal carcinomas [1,6].
Epidemiological studies have revealed the association of
high concentrations of serum IGF-I and IGF-II with the in-
creased risk of developing several human cancers including
colorectal carcinomas [7-10]. Examination of colorectal
carcinomas has revealed elevation of the transcripts of
IGF-I/II [11-13] and IGF-1R [14,15]. These findings
suggest that IGF-I/II may interact with IGF-1R on the
cancer cell surface and promote cancer growth through
paracrine and autocrine loops and targeting of the IGF-
IGF-1R pathway may lead to the development of cancer
therapeutics [6]. IGF-1R has been targeted by two types of
therapeutic agents: IGR-1R neutralizing monoclonal
antibodies and small molecule IGF-1R inhibitors [16,17].
Monoclonal antibodies and kinase inhibitors have been
characterized in preclinical studies [18] and some have
been taken to clinical trials for cancer treatments [19,20].
Preliminary data from current clinical trials have revealed
resistance of human cancers to treatment [1,16]. For
example, a phase II trial of an IGF-1R antibody has
shown a limited response with treatment of metastatic
colorectal carcinomas [21].
The characterization of the crystallographic structures
of the insulin receptor and IGF-1R has enabled the devel-
opment of IGF-1R specific inhibitors [22-24]. Picropodo-
phyllin (PPP), a member of the cyclolignan family, has been
identified as an IGF-1R inhibitor [25] since it specifically
blocks the phosphorylation of the Tyr 1136 residue in the
IGF-1R activation loop and thus inhibits the phosphoryl-
ation and kinase activity of the receptor [26]. PPP blocks
the PI3K/AKT pathway [25], induces apoptosis in multiplemyeloma cells [27], and suppresses the growth of multiple
myeloma and glioblastoma xenografts [28-30]. Phase I/II
trials have been launched for treatment of glioblastoma,
hematological malignancies, and non-small cell lung carcin-
oma by picropodophyllin (AXL1717).
In this study, we investigated the therapeutic response of
human colorectal carcinomas with the recently identified
IGF-1R inhibitor, PPP [25]. Multiple colorectal carcinoma
cell lines were used in addition to colorectal xenografts
generated in mice to study the therapeutic response.
We examined the IGF-1R downstream AKT and ERK
growth pathways and BAD-mediated mitochondrial
apoptotic pathway in PPP-treated colorectal carcinoma
cells. These studies found the majority of the carcinoma cell
lines were resistant to PPP treatment due to the failure
of AKT and ERK activation as well as induction of BAD-
mediated mitochondrial apoptotic pathways. Furthermore,
these studies revealed the association of TP53 mutations
with PPP resistance in the carcinoma cell lines in cul-
ture and a xenograft model. While human colorectal
carcinomas harbor frequent mutations of APC, TP53,
PIK3CA and KRAS [31], our findings suggest that the
TP53 mutations are associated with the resistance of
colorectal carcinoma to the IGF-1R inhibitor, PPP.
Methods
Human colorectal carcinoma cell lines, tumors and
normal colon tissues
Human colorectal carcinoma cell lines CACAO-2, COLO-
205, COLO-320, DLD-1, HCT-8, HT29 and SW948
were purchased from American Type Collection (ATCC;
Rockville, MD). Each cell line was grown in RPMI1640
medium (Invitrogen, Carlsbad, CA) supplemented with
10% fetal bovine serum (FBS). Cells were maintained in a
humidified 37°C and 5% CO2 incubator. Human colorectal
carcinoma and matched adjacent normal colorectal tissue
samples were collected in accordance with the protocols
approved by the institutional Review Board of the First
Hospital of Jilin University. All patients provided writ-
ten informed consent for the tissue sample collection.
This study was approved by the First Hospital Ethical
Committee of Jilin University.
IGF-1R inhibitor and antibodies
PPP were purchased from Calbiochem (EMD Millipore)
and dissolved in dimethyl sulfoxide (DSMO) at the concen-
tration of 10 mM and stored in aliquots at −80°C. Recom-
binant human IGF-I was also purchased from Calbiochem
and stored in aliquots at −80°C. The antibodies used in
this study were purchased from Cell Signaling Technology
(Beverly, MA) against the human caspase-9, phospho-
IRS-1, AKT, phospho-AKT (Ser473), ERK, phopho-ERK
(Thr202/Thr204), IGF-1R, phospho-IGF-1R (Y1135/1136),
BAD and phospho-BAD (Ser112/Ser136). Other primary
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human poly (ADP-ribose) polymerase (PARP), caspase-3
(StressGen, Ann Harbor, MI), DNF fragmentation factor-45
(DFF45), β-actin, BCL-2 (Santa Cruz Biotechnology, Santa
Cruz, CA), MDM2 (sigma Aldrich) and X-linked inhibitor
of apoptosis protein (XIAP; Transduction Laboratories,
Lexington, KY). The secondary antibodies used in this
study were horseradish peroxidase (HRP)-conjugated goat
anti-mouse (Southern Biotech, Birmingham, AL) and
goat anti-rabbit antibody (Jackson ImmunoResearch
Laboratories, West Grove, PA). Protease inhibitor mixture,
Triton x-100 and other chemicals were purchased from
Sigma-Aldrich. Chemiluminescence was from Amersham
Biosciences (Piscataway, NJ).
Cell viability assay
Cells were grown in 96-well plates at 8x103 cells per well in
100 μl of growth medium. Cells were treated or untreated
with PPP in the concentrations as indicated in the Results.
After incubation for the times indicated in the Results, cells
were washed with a phosphate buffer and 100 μl buffer
0.2 M containing sodium acetate (pH 5.5), 0.1% (v/v) Triton
X-100 and 20 mM p-nitrophenyl phosphate was added to
each of the wells. The plates were incubated at 37°C for
1.5 hours and the reaction was stopped by the addition of
10 μl 1 M NaOH to each well, Absorbance were measured
at 405 nm by a microplate reader (BioRad).
Flow cytometric assay for the cell cycle and sub-G1
apoptotic cells
Cells were treated with 1 μM PP242 and 2 μM erlotinib,
alone or in combination, for 20 hours, harvested, fixed with
70% ethanol, and stained with propidium iodide. The data
were acquired using flow cytometry (FACSCanto II Becton
Dickinson, Franklin Lakes, NY) and were analyzed using
FlowJo software (Tree Star Inc. Ashland, OR). Sub-G1
apoptotic cells were determined as a percentage of the cells.
Western blotting
Western blotting was performed according to our la-
boratory protocols [32]. In brief, cells were lysed in a
cell lysis buffer (20 nM Tris pH7.4, 150 mM NaCL, 1%
NP-40, 10% glycerol,1 mM EGTA, 1 mM EDTA, 5 mM
sodium pyrophosphate, 50 mM sodium fluoride, 10 mM
β-glycerophosphate, 1 mM sodium vanadate, 0.5 mM DTT,
1 mM PMSF, 2 mM imidazole, 1.15 mM sodium molyb-
date, 4 mM sodium tartrate dihydrate, and 1x protease in-
hibitor cocktail). Cell lysates were cleared by centrifugation
at 18,000 x g for 15 minutes at 4°C. The supernatant was
collected and protein concentrations were determined by
the Bradford protein assay following the manufacturer’s
protocol (Bio-Rad Laboratories). Equal amounts of protein
were separated through SDS-PAGE gels and transferred
onto nitrocellulose membranes (Bio-Rad Laboratories). Themembranes were incubated overnight at 4°C with pri-
mary antibody and then for 1 hour with HP-conjugated
secondary antibody. The membranes were developed
by chemiluminescence.
Mouse subcutaneous xenografts and treatments
The animal studies were approved by the Institutional
Animal Care and Use Committee of Emory University.
The HCT-8 cells or Caco2 cells (7 × 106) were implanted
subcutaneously into the flank regions of six-week old
(about 20 g of body weight) female athymic (nu/nu) mice
(Taconic, Hudson, NY). The mice were allowed to develop
subcutaneous xenografts and tumor volumes were mea-
sured using caliper measurements. When tumors reached
approximately 150–200 mm3, mice were assigned ran-
domly to 2 experimental groups (n = 4 per group) and
treated either with saline as control or PPP (50 mg/kg)
through oral gavages, twice per week. Tumor volumes
were measured once every 3 days and calculated based
on the formula: V =4/3 × π × (length/2 × [width/2]2). At
the end of treatment, the mice were sacrificed and the tu-
mors were harvested and weighed at necropsy.
Statistical analysis
All data were presented as means ± SE. Statistical analyses
were performed by GraphPad Prism version 5.01 software
for Windows (GraphPad Software). The differences in the
means between two groups were analyzed with two-tailed
unpaired Student’s t-test. Results were considered to be
statistically significant at P <0.05.
Results
TP53 mutated colorectal carcinoma cells are resistant to
PPP treatment
Earlier studies have revealed increased levels of the IGF-1R
mRNA in human colorectal carcinoma tumors [14,15].
To examine the expression of IGF-1R protein, we carried
out a western blot analysis of human colorectal carcinoma
tumors, together with matched normal colorectal tissue.
The results showed that IGF-1R proteins were expressed
in the carcinoma tumors at much higher levels than in the
matched normal tissue (Figure 1A). We then examined a
panel of seven colorectal carcinoma cell lines by western
blotting and identified the expression of IGF-1R in each of
these cell lines. Nearly half of the cell lines expressed
much higher levels of IGF-1R as compared with other cell
lines (Figure 1B).
Next, we examined how colorectal carcinoma cell lines
respond to PPP treatment. To this end, each of the cell
lines was treated with a series of PPP concentrations
for 72 hours. A cell viability assay showed PPP treat-
ment significantly inhibited the growth of the sensitive
cell lines HCT-8 and SW948. Slight inhibition of the
growth of the resistant cell lines CACO-2, COLO-205,
Figure 1 TP53 mutation is associated with PPP resistance in colorectal carcinoma cells. (A). Western blot analysis of the expression of
IGF-1R protein in colorectal carcinoma tumor tissues (T) and matched adjacent normal colorectal tissue (N). β-actin was used as the protein
loading control. (B). Western blot detection of IGF-1R protein in a panel of seven colorectal carcinoma cell lines as indicated on the top of the
panel. (C). Each of the cell lines was treated with the indicated concentrations of PPP for 72 hours and then analyzed by cell viability assay.
The experiment was repeated three times and the data presented as mean + SD (standard deviation). **, p < 0.01.
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higher doses (Figure 1C). The PPP resistant cell lines
were reported with TP53 mutations [33] according to the
Catalogue of Somatic Mutations in Cancer (http://cancer.
sanger.ac.uk/cancergenome/projects/cosmic). In contrast,
HCT-8 [34] and SW948 (http://cancer.sanger.ac.uk/
cancergenome/projects/cosmic) are TP53 wild-type cell
lines. These analyses suggest the association of TP53
mutations with the PPP resistance of colorectal carcinoma
cells to PPP treatment.
PPP treatment enhances AKT and ERK phosphorylation in
TP53 mt carcinoma cells
To examine the mechanism of PPP resistance, we
evaluated whether PPP treatment blocks IGF-1R auto-
phosphorylation [26] and inhibits the downstream AKT
and ERK pathways [25]. Since IGF-I and IGF-II activate
IGF-1R through paracrine and autocrine loops [6], each
of the cell lines was therefore treated with 50 ng IGF-I.
Western blotting showed that the IGF-I treatment resulted
in the phosphorylation of IGF-1R in both the TP53
wild-type HCT8 and mutated CACO-2 cells (Figure 2A).
The cell lines were then treated with 500 nM PPP in the
presence of IGF-I and western blotting revealed a decrease
in phosphorylation of IGF-1R in a time dependent manner.
In contrast, total IGF-1R levels remained unchanged during
the treatment. These data indicate that PPP blocks IGF-1R
phosphorylation in both TP53 wild-type and mutated
cells. PPP treatment reduced the levels of phosphorylated
AKT and ERK in the TP53 wild-type HCT-8 but not the
TP53 mutated CACO-2 cells; the results suggest that the
PPP resistance occurs at IGF-1R downstream intracellular
levels in TP53mutated cells.
Earlier studies have clearly shown that PPP treatment
leads to the downregulation of IGF-1R through MDM2-
mediated ubiquitination and degradation of the IGF-1Rprotein [35]. Both IGF-1R and p53 proteins are the sub-
strates of the ubiquitin ligase MDM2 [36]. To explore the
role of MDM2 in the resistance of mutated TP53 cell lines
to PPP, we examined the protein levels of MDM2 in wild-
type and mutated TP53 cell lines by western blotting. The
data revealed no difference in the expression of MDM2
protein between TP53 wild-type and mutated cell lines
(Figure 2B). Next, we examined the kinetics of IGF-1R
degradation under the treatment of IGF-1 and PPP, alone
and in combination. To this end, we compared the IGF-1R
protein levels between the TP53 wild-type SW948 and
mutated CACO-2 since these two cell lines expressed
IGF-1R protein at similar levels (Figure 1B). Western
blotting revealed that PPP treatment reduced the levels
of IGF-1R protein in both SW948 and CACO-2 cells
(Figure 2C) due to the similar expression levels of MDM2
protein between these two cell lines (Figure 2B). These re-
sults confirm the earlier reports [35,36] that PPP treatment
induces IGF-1R degradation through MDM2-medicated
ubiquitination in a p53-independent manner.
MDM2-mediated ubiquitination of IGF-1R with PPP
treatment leads to the activation of ERK pathway [37],
resulting in the resistance of Ewing’s sarcoma to the
treatment of the anti-IGF-1R antibody figitumuab [38].
To explore this mechanism in colorectal carcinoma,
we treated SW948 and CACO-2 cell lines with PPP in
a dose-dependent manner and found that PPP treat-
ment increased the levels of p-ERK in the TP53 mu-
tated CACO-2 but not in the TP53 wild-type SW948
cells (Figure 2D). Taken together, the results suggest
that PPP treatment bocks the phosphorylation of IGF-
1R and inhibits the downstream ERK pathway in TP53
wild type colorectal carcinoma cells. In contrast, TP53
mutated carcinoma cells are resistant to the PPP treat-
ment in part due to its failure of inhibition of the intra-
cellular ERK pathway.
Figure 2 PPP treatment triggers apoptosis in TP53 wild-type but not mutated cells. (A). The TP53 wild-type HCT-8 and mutated CACO-2
cells were treated with 500 nM PPP in the presence or absence of 50 ng/ml IGF-I for the hours as indicated. The treated cells were then examined
by western blotting for the presence of the phosphorylated and unphosphorylated IGF-1R, AKT and ERK with β-actin as the loading control.
(B). The TP53 wild-type HCT8 and SW948 and mutated CACO-2 and HT29 were examined by western blotting for the levels of MDM2 protein.
(C). The TP53 wild-type SW948 and mutated CACO-2 cells were treated with 500 nM PPP and 50 ng/ml IGF-I, alone and in combination, for the
indicated hours. The cells were then examined by western blotting for the levels of IGF-1R protein. (D). SW948 and CACO-2 cells were treated with 500
nM PPP for the indicated minutes and then analyzed by western blotting for the levels of unphosphorylated and phosphorylated ERK (p-ERK).
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not mutated carcinoma cells
Earlier studies have shown that PPP treatment inhibits cell
growth and induces apoptosis in different types of cancer
cells [25,27]. To examine this in colorectal carcinoma cells,
we analyzed PPP-treated cells by flow cytometry. The
results showed that PPP treatment led to a significant
increase of sub-G1 apoptotic cells in the TP53 wild-type
but not mutated cell lines (Figure 3A,B). The results further
suggest that TP53 mutated carcinoma cells are resistant
to PPP treatment in part due to its failure of induction
of apoptosis in these cells.
IGF-1R activation leads to the inhibition of apoptosis
through the AKT/ERK-mediated phosphorylation of BAD
[3]. The failure in AKT/ERK activation and apoptosis
induction in TP53 mutated cells under PPP treatment
suggests the possibility that BAD phosphorylation may
play a role in the PPP resistance. To test this notion, we
treated the TP53 wild type HCT-8 and mutated CACO-2
cells with 500 nM PPP. Lysates from the treated cells were
examined by western blot analysis using antibodies against
the phosphorylated and unphosphorylated form of BAD.
The results showed that the PPP treatment inhibited
BAD phosphorylation in TP53 wild-type but not mutated
cells (Figure 4A).
Unphosphorylated BAD interacts with the BCL2 family
of proteins and releases their inhibition of the mitochon-
drial membrane potential [4], leading to the mitochondrial
release of apoptosis factors and resulting in caspase-9activation and initiation of apoptosis through cleavage
of the downstream effectors caspase-3, DFF45, and PARP
[39]. In addition, the second mitochondria-derived activator
of caspase/direct inhibitor of apoptosis binding protein with
low pI (SMAC/DIABLO) interacts with THE X-linked
inhibitor of apoptosis protein (XIAP), which releases XIAP
from binding to caspase-3 and allows caspase-9 cleavage of
caspase-3 [40,41]. To examine this mitochondrial pathway
in PPP-induced apoptosis, we showed that the treatment of
PPP led to the cleavage of XIAP (Figure 4A) and caspase-9,
caspase-3, PARP, and DFF45 in the TP53 wild-type HCT-8
but not the mutated CACO-2 cells (Figure 4B). Collectively,
the PPP resistance is in part due to the inhibition of
BAD-mediated mitochondrial apoptosis in TP53 mutated
colorectal carcinoma cells.
PPP treatment inhibits TP53 wild type but not mutated
colorectal carcinoma xenografts
To examine the potential of PPP in treatment of colorectal
carcinoma, we first injected the TP53 wild-type HCT-8
cells subcutaneously in athymic (nu/nu) mice for the gen-
eration of subcutaneous flank xenografts. The mice were
closely monitored and once xenografts reached approxi-
mate size of 150–200 mm3, the mice were divided into
two groups. In the treatment group, mice were treated
with PPP (50 mg/kg) and in the control group, mice were
treated with saline. The mice were treated through oral
gavage, twice per week for three weeks. Tumor volumes
were measured and the results showed that PPP treatment
Figure 3 PPP treatment triggers apoptosis in TP53 wild type but not mutated cells. (A). Each of the cell lines was treated with 500 nM PPP
for 24 hours and subjected to flow cytometry for the detection of the cells in sub-G1 and cell cycle phases. (B). The experiment was repeated
three times and the percentage of sub-G1 apoptotic cells is summarized in this histogram as mean + SD. **, p < 0.01.
Figure 4 PPP resistance is in part due to the inhibition of BAD-mediated mitochondrial pathway. (A). The TP53 wild type HCT-8 and mutated
CACO-2 were treated with 500 nM PPP for the indicated hours and then subjected to western blotting for the presence of the phosphorylated and
unphosphorylated BAD and cleavage of XIAP protein. (B). The PPP treated cells were further examined by western blotting for the cleavage of
caspase-9, caspase-3, PARP and DFF45 in HCT-8 and CACO-2 cells with the proteins and cleavage products indicated to the right side of the panel.
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HCT-8 colorectal carcinoma xenografts (Figure 5A).
At necropsy, a significant difference in the tumor sizes
was observed between the control and treatment mice
(Figure 5B). The xenografts were removed and tumor ly-
sates were subjected to western blot analysis. The results
showed that PPP treatment inhibited the phosphorylation
of IGF-1R, AKT, and ERK in the TP53 wild-type HCT-8
colorectal carcinoma xenografts (Figure 5C).
To examine whether the TP53 mutated colorectal car-
cinoma xenografts resist the treatment of PPP, we injected
CACO-2 cells subcutaneously in athymic (nu/nu) mice.
Once subcutaneous xenografts were formed approximately
150–200 mm3 in size, the mice were treated either with
PPP (50 mg/kg) or saline through oral gavage, twice per
week for three weeks. The results showed no significant
difference in the tumor sizes between the treatment and
control group of mice, as indicated by the measured tumor
volumes (Figure 6A) and the tumor sizes as observed at
necropsy (Figure 6B). Western blot analysis of the repre-
sentative xenograft tissues showed that PPP treatment
failed to inhibit the phosphorylation of IGF-1R, AKT and
ERK in the TP53 mutated CACO-2 colorectal carcinoma
xenografts (Figure 6C). Taken together, these studies sug-
gest that TP53 wild type colorectal carcinoma may respond
to the treatment of PPP whereas TP53 mutated carcinomas
are most likely resistant to the treatment.
Discussion
Colorectal carcinoma is the second leading cause of cancer-
related deaths in the United States [42]; thus, there is an
urgent need for the development of novel and effective
treatment of this devastating human disease. Recent stud-
ies have provided several lines of evidence indicating that
targeting of IGF-1R may as serve as the basis for clinical
treatment of colorectal carcinoma. High concentrations ofFigure 5 PPP treatment inhibits the growth of TP53 wild type carcino
athymic mice for xenograft formation. Once the xenografts were formed, t
group or saline in the control group through oral gavage, twice per week.
presented as mean ± SD. **, p < 0.01. (B). The representative mice bearing
left and PPP-treated mouse on the right. (C). The preventative xenograft tu
subjected to western blotting for the presence of the phosphorylated andserum IGF-I/IGF-II are associated with increased risk
for developing colorectal carcinoma [7-9] and the IGF-II
gene is the single most overexpressed gene in colorectal
carcinomas [43]. Furthermore, colorectal carcinomas
express high levels of IGF-I/IGF-II [11-13], IGF-1R mRNA
[14,15], and IGF-1R protein, as shown in this study.
The higher expression levels of IGF-1R are associated
with a higher malignant pathologic grade and late stage
of colorectal carcinomas [44].
Preclinical studies have shown that the GEO colorectal
carcinoma cell line and xenografts respond to the treat-
ment of a dual IGF-1R/insulin receptor kinase inhibitor,
PQIP [45]. However, examination of a large panel of colo-
rectal carcinoma cell lines has suggested that the majority
of the cell lines are resistant to this dual inhibitor [46].
The combined treatment of the IGF-1R kinase inhibitor,
NVP-AFW541 or PQIP with the epidermal growth factor
receptor (EGFR) inhibitor erlotinib or tarceva triggers
apoptosis and inhibits growth of colorectal carcinoma cell
lines [47,48]. A phase II trial, however, has concluded that
the IGF-1R neutralizing antibody IMC-A12, alone or
in combination with the EGFR antibody cetuximab, is
insufficient for the treatment of colorectal carcinomas
[21]. Currently, clinical trials of IGF-1R antibodies and
kinase inhibitors are ongoing in treating various hu-
man cancers. These trails may benefit from studies of
the mechanisms in drug resistance and identification
of biomarkers that can predict cancer responsiveness
to IGF-1R targeted therapies.
After examining a panel of colorectal carcinoma cell lines
and xenografts, we have found that the cell lines respond
differently to the treatment of PPP, an IGF-1R inhibitor
[25]. Some of the cell lines are sensitive whereas other
cell lines are resistant to PPP treatment. In the sensitive
lines HCT-8 and SW948, PPP treatment blocks IGF-1R
phosphorylation and inhibits its downstream AKTand ERKma xenografts. (A). HCT-8 cells were injected subcutaneously in
he mice were treated either with PPP (50 mg/kg) in the treatment
The tumor volumes from the same group of mice were grouped and
xenografts were shown at necropsy with saline-treated mouse on the
mors (T) from saline treated (−) and PPP treated mice (+) were
unphosphorylated IGF-1R, AKT and ERK.
Figure 6 TP53 mutated colorectal carcinoma xenografts are resistant to PPP treatment. (A). The TP53 mutated CACO-2 cells were injected
subcutaneously in mice and once the subcutaneous xenografts were formed, the mice were treated either with PPP (50 mg/kg) or saline through
oral gavage, twice per week. The tumor volumes from the same group of mice were grouped and presented as mean ± SD. **, p < 0.01. (B). The
mice bearing xenografts were shown at necropsy with a saline-treated mouse on the left and a PPP-treated mouse on the right. (C). The xenograft
tumors (T) from saline treated (−) and PPP treated mice (+) were examined by western blotting for the presence of the phosphorylated
and unphosphorylated IGF-1R, AKT and ERK.
Wang et al. BMC Cancer 2013, 13:521 Page 8 of 10
http://www.biomedcentral.com/1471-2407/13/521pathway, and suppresses carcinoma cell growth and
xenograft progression. In addition, PPP treatment blocks
BAD phosphorylation and activates BAD-mediated
apoptosis through the mitochondrial pathway. These
findings are consistent with other reports that PPP
treatment triggers apoptosis in multiple myeloma cells [27]
and suppresses the progression of multiple myeloma
and glioblastoma xenografts [28-30]. Phase I/II trails
of PPP are currently in place for treating patients with
glioblastoma, hematological malignancies, and non-small
cell lung carcinoma.
The salient feature of this study is that most colorectal
carcinoma cell lines are resistant to the treatment of
PPP. PPP treatment does block IGF-1R phosphorylation
but fails to inhibit the downstream AKT and ERK pathway
or induce BAD-mediated mitochondrial apoptosis. These
findings are consistent with the clinical trials of IGF-1R
targeted agents that have not shown much clinical activity
against human cancers [1,16]. Our data suggest that the
lack of therapeutic effect is due to the association of PPP
resistance with TP53 mutations in colorectal carcinomas.
The p53 tumor suppressor regulates apoptosis in many
types of cells and mutations of the TP53 gene result in the
loss of its function in control of apoptosis in cancer cells
[49]. TP53 mutations commonly occur in human colorec-
tal carcinomas [31]. Our study suggests that TP53 gene
status can be used as a biomarker to predict the respon-
siveness of colorectal carcinomas to the treatment of IGF-
1R targeted therapies.
The discovery of PPP as an IGF-1R inhibitor [25] by a
research group at the Karolinska Institute has revealed
its mechanism of action through inhibition of IGF-1R
phosphorylation [26], which induces G2/M-phase ac-
cumulation and apoptosis [27]. This group has further
shown that PPP treatment down-regulates the IGF-1R
protein through MDM2-mediated ubiquitination anddegradation [35]. The MDM2-mediated IGF-1R ubiquitina-
tion activates the ERK pathway [37] and leads to the cancer
resistance to PPP [38]. The data presented in this manu-
script have confirmed the action of PPP in inhibition of
cell growth and induction of apoptosis in TP53 wild-type
colorectal carcinoma cells. We have also found a correl-
ation between TP53 mutation and PPP resistance in human
colorectal carcinoma cells. Both p53 and IGF-1R proteins
are the substrates of MDM2 and the presence of MDM2 in
both TP53 wild-type and mutated carcinoma cells suggests
that PPP-induced ERK activation in TP53 mutated carcin-
oma cells occurs through a p53-independent manner.
The PPP-induced ERK activation contributes in part to
the resistance of TP53 mutated colorectal carcinoma to
the IGF-1R inhibitor PPP.
Conclusions
The IGF-1R inhibitor, PPP, is currently in clinical trials
for the treatment of human cancers. We have found the
majority of colorectal carcinoma cell lines are resistant to
PPP treatment due to failure of activation of the intracel-
lular AKT and ERK growth pathway and induction of the
BAD-induced mitochondrial apoptosis pathway. Further-
more, we have found that TP53 mutations are associated
with PPP resistance in colorectal carcinoma and indicated
that determining the TP53 gene status as wild-type or mu-
tated can be used as a biomarker to predict the respon-
siveness of colorectal carcinoma in human clinical trials.
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